Important Content Reminder:
- Beijing Saiseng Pharmaceutical Co., Ltd. (hereinafter referred to as "the Company") intends to extend the financial assistance provided to its subsidiary, Beijing Sai'er Bio Pharmaceutical Co., Ltd. (hereinafter referred to as "the subsidiary" or "Sai'er Bio"), with the loan term extended to March 28, 2029, at an annual interest rate of 3%.
- This financial assistance extension has been approved by the special meeting of independent directors of the Company's fifth board of directors at its first meeting in 2026 and the thirteenth meeting of the fifth board of directors, and does not require submission to the shareholders' meeting for approval.
- The financial assistance extension is directed towards a subsidiary within the Company's consolidated financial statements, over which the Company has substantial control, allowing effective business and financial management risk control to ensure the safety of the Company's funds. The overall risk of this financial assistance extension is controllable, and there is no harm to the Company and its shareholders, especially minority shareholders.
I. Overview of the Financial Assistance Extension
(1) Basic Information
The Company approved the proposal to provide financial assistance to Sai'er Bio at the twenty-fourth meeting of the fourth board of directors held on April 24, 2023, agreeing to use its own funds to provide a total of no more than 20 million RMB in financial assistance, with a loan term not exceeding 36 months, and the interest calculated at the same rate as bank loans during the period. Given that the loan term is about to expire, and based on recognition of Sai'er Bio and confidence in its future development, the Company intends to extend the financial assistance of no more than 20 million RMB to Sai'er Bio, with the loan term extended to March 28, 2029, and the interest calculated at an annual rate of 3%. The Company and all members of the board guarantee that the content of the information disclosure is true, accurate, and complete, with no false records, misleading statements, or significant omissions.
This financial assistance extension does not affect the normal business operations and fund usage of the Company and does not fall under the circumstances prohibited for providing financial assistance as per the Shenzhen Stock Exchange's "Rules for Listing of Growth Enterprise Market Stocks" and "Guidelines for Standardized Operations of the Growth Enterprise Market."